Cargando…

Growth pattern can be used as a new characteristic to predict malignancy in breast cancer

BACKGROUND: To date, anatomic tumor length is a key criterion for cancer staging and can be used to evaluate the effectiveness of therapies. This article describes growth pattern that can be used as a new characteristic to represent disease burden and tumor features and predict lymphatic metastasis....

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Bin, Zhu, Lizhe, He, Chenyang, Tai, Minghui, Zhou, Can, Ge, Guanqun, Zhang, Huimin, He, Jianjun, Wang, Ke
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Japan 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7196087/
https://www.ncbi.nlm.nih.gov/pubmed/32030658
http://dx.doi.org/10.1007/s12282-019-01041-7
_version_ 1783528654306803712
author Wang, Bin
Zhu, Lizhe
He, Chenyang
Tai, Minghui
Zhou, Can
Ge, Guanqun
Zhang, Huimin
He, Jianjun
Wang, Ke
author_facet Wang, Bin
Zhu, Lizhe
He, Chenyang
Tai, Minghui
Zhou, Can
Ge, Guanqun
Zhang, Huimin
He, Jianjun
Wang, Ke
author_sort Wang, Bin
collection PubMed
description BACKGROUND: To date, anatomic tumor length is a key criterion for cancer staging and can be used to evaluate the effectiveness of therapies. This article describes growth pattern that can be used as a new characteristic to represent disease burden and tumor features and predict lymphatic metastasis. METHODS: Patients with breast cancer were included in this 10-year (1999–2008) hospital-based multicenter retrospective study. The pathologic length/height ratio was used to illustrate the correlation between tumor features, behaviors and treatments in breast malignancies. The most appropriate ratio was chosen based on the comprehensive evaluation of p value and changing trend of each characteristic. RESULTS: The sample consisted of 4211 women diagnosed with breast cancer. Among them, 2037 patients with complete pathologic length, width and height information were included in the final analysis. There were 2.34 ± 4.77 metastatic lymph nodes for spheroid tumors and 3.21 ± 5.82 for ellipsoid tumors when the cutoff point was 2. In addition, the proportion of ellipsoidal tumors gradually increased from 54.36 to 56.67% in the upper outer quadrant (UOQ) and from 6.7 to 9.03% in the central region with an increase in the cutoff point. The proportion of ER + PR + ellipsoid tumors significantly decreased from 50.1 to 45.35% and that of ER–PR ellipsoid tumors significantly increased from 32.73 to 36.24% with an increase in the cutoff point. Additionally, the best length/weight ratio to distinguish spheroid and ellipsoid tumors was 2. CONCLUSION: This study described for the first time how growth pattern is correlated with tumor malignancy and how it influences the selection of therapeutic strategies for patients. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (10.1007/s12282-019-01041-7) contains supplementary material, which is available to authorized users.
format Online
Article
Text
id pubmed-7196087
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Springer Japan
record_format MEDLINE/PubMed
spelling pubmed-71960872020-05-05 Growth pattern can be used as a new characteristic to predict malignancy in breast cancer Wang, Bin Zhu, Lizhe He, Chenyang Tai, Minghui Zhou, Can Ge, Guanqun Zhang, Huimin He, Jianjun Wang, Ke Breast Cancer Original Article BACKGROUND: To date, anatomic tumor length is a key criterion for cancer staging and can be used to evaluate the effectiveness of therapies. This article describes growth pattern that can be used as a new characteristic to represent disease burden and tumor features and predict lymphatic metastasis. METHODS: Patients with breast cancer were included in this 10-year (1999–2008) hospital-based multicenter retrospective study. The pathologic length/height ratio was used to illustrate the correlation between tumor features, behaviors and treatments in breast malignancies. The most appropriate ratio was chosen based on the comprehensive evaluation of p value and changing trend of each characteristic. RESULTS: The sample consisted of 4211 women diagnosed with breast cancer. Among them, 2037 patients with complete pathologic length, width and height information were included in the final analysis. There were 2.34 ± 4.77 metastatic lymph nodes for spheroid tumors and 3.21 ± 5.82 for ellipsoid tumors when the cutoff point was 2. In addition, the proportion of ellipsoidal tumors gradually increased from 54.36 to 56.67% in the upper outer quadrant (UOQ) and from 6.7 to 9.03% in the central region with an increase in the cutoff point. The proportion of ER + PR + ellipsoid tumors significantly decreased from 50.1 to 45.35% and that of ER–PR ellipsoid tumors significantly increased from 32.73 to 36.24% with an increase in the cutoff point. Additionally, the best length/weight ratio to distinguish spheroid and ellipsoid tumors was 2. CONCLUSION: This study described for the first time how growth pattern is correlated with tumor malignancy and how it influences the selection of therapeutic strategies for patients. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (10.1007/s12282-019-01041-7) contains supplementary material, which is available to authorized users. Springer Japan 2020-01-03 2020 /pmc/articles/PMC7196087/ /pubmed/32030658 http://dx.doi.org/10.1007/s12282-019-01041-7 Text en © The Author(s) 2020 Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.
spellingShingle Original Article
Wang, Bin
Zhu, Lizhe
He, Chenyang
Tai, Minghui
Zhou, Can
Ge, Guanqun
Zhang, Huimin
He, Jianjun
Wang, Ke
Growth pattern can be used as a new characteristic to predict malignancy in breast cancer
title Growth pattern can be used as a new characteristic to predict malignancy in breast cancer
title_full Growth pattern can be used as a new characteristic to predict malignancy in breast cancer
title_fullStr Growth pattern can be used as a new characteristic to predict malignancy in breast cancer
title_full_unstemmed Growth pattern can be used as a new characteristic to predict malignancy in breast cancer
title_short Growth pattern can be used as a new characteristic to predict malignancy in breast cancer
title_sort growth pattern can be used as a new characteristic to predict malignancy in breast cancer
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7196087/
https://www.ncbi.nlm.nih.gov/pubmed/32030658
http://dx.doi.org/10.1007/s12282-019-01041-7
work_keys_str_mv AT wangbin growthpatterncanbeusedasanewcharacteristictopredictmalignancyinbreastcancer
AT zhulizhe growthpatterncanbeusedasanewcharacteristictopredictmalignancyinbreastcancer
AT hechenyang growthpatterncanbeusedasanewcharacteristictopredictmalignancyinbreastcancer
AT taiminghui growthpatterncanbeusedasanewcharacteristictopredictmalignancyinbreastcancer
AT zhoucan growthpatterncanbeusedasanewcharacteristictopredictmalignancyinbreastcancer
AT geguanqun growthpatterncanbeusedasanewcharacteristictopredictmalignancyinbreastcancer
AT zhanghuimin growthpatterncanbeusedasanewcharacteristictopredictmalignancyinbreastcancer
AT hejianjun growthpatterncanbeusedasanewcharacteristictopredictmalignancyinbreastcancer
AT wangke growthpatterncanbeusedasanewcharacteristictopredictmalignancyinbreastcancer